age-related macular degeneration
PulseSight Therapeutics closes Series A financing for dry AMD phase 1 clinical study
February 14, 2025Clinical Research Opthalmology, age-related macular degeneration, clinical trials
Ophthalmology biotech PulseSight Therapeutics has confirmed the closure of its Series A funding round, the proceeds of which will be …
Common diabetes drug can protect against age-related macular degeneration, research shows
October 31, 2018Research and Development age-related macular degeneration, diabetes, eye, metformin, pharma
A Taiwanese research team has demonstrated a link between the use of the common diabetes medication metformin and significantly lower …
Bayer’s challenger to Lucentis shows promise
November 22, 2010Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD
Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …
Latest content
Five Facts about NHS and primary care
September 5, 2026
AI in pharma: From lab development to patient impact
September 5, 2026
